Cure of disseminated xenografted human Hodgkin's tumors by bispecific monoclonal antibodies and human T cells: The role of human T-cell subsets in a preclinical model

Blood

Volumn 87, Issue 7, 1996, Pages 2930-2937

  Renner, Christoph ^b   Bauer, Stefan ^b   Sahin, Ugur ^b   Jung, Wolfram ^b   Van Lier, Rene ^b   Jacobs, Georg ^b   Held, Gerhard ^b   Pfreundschuh, Michael ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BISPECIFIC ANTIBODY; CD28 ANTIGEN; CD3 ANTIGEN; CD30 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; MONOCLONAL ANTIBODY; T LYMPHOCYTE ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; HODGKIN DISEASE; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; SURVIVAL; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME; TUMOR XENOGRAFT;

EID: 0030007378     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v87.7.2930.bloodjournal8772930     Document Type: Article

References (24)

1. Milstein C, Cuello AC: Hybrid hybridomas and their use in immunohistochemistry. Nature 305:537, 1983
2. Hombach A, Jung W, Pohl C, Renner C, Sahin U, Schmits R, Wolf J, Kapp U, Diehl V, Saules C, Pfreundschuh M: A CD16/ CD30 bispeeific antibody induces lysis of Hodgkin cells by unstimulated natural killer cells in vitro and in vivo. Int J Cancer 55:830, 1993
3. Pohl C, Denfeld R, Renner C, Jung W, Bohlen H, Sahin U, Hombach A, van Lier R, Schwonzen M, Diehl V, Pfreundschuh M: CD30 antigen specific targeting and activation of T cells via murine bispecific monoclonal antibodies against CD3 and CD28: Potential use for the treatment of Hodgkin's lymphoma. Int J Cancer 54:820, 1993
4. Lanier LL, Yu G, Philipps JH: Co-association of CD3ζ with a receptor (CD16) for IgG Fc on human natural killer cells. Nature 342:803, 1989
5. Anegon I, Cuturi MC, Trinchieri G, Perussia B: Interaction of Fc receptor (CD16) with ligands induces transcription of IL-2 receptor (CD25) and lymphokine genes and expression of their products in human natural killer cells. J Exp Med 167:452, 1988
6. June CH, Ledbetter JA, Linsley P, Thompson CB: Role of the CD28 receptor in T cell activation. Immunol Today 11:211, 1990
7. Harding FA, McArthur JG, Gross HA, Raulet DH, Allison JP: CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 356:607, 1992
8. Staerz UD, Bevan JM: Hybrid hybridoma producing a bispecific monoclonal antibody that can focus effector T-cell activity. Proc Natl Acad Sci USA 83:1453, 1986
9. Jung G, Ledbetter JA, Müller-Eberhard HJ: Induction of cytotoxicity in resting human T lymphocytes bound to tumor cells by antibody heteroconjugates. Proc Natl Acad Sci USA 84:4611, 1987
10. Weiner GJ, Hillstrom JR: Bispecific anti-idiotype/anti-CD3 antibody therapy of murine B cell lymphoma. J Immunol 147:4035, 1991
11. Möller SA, Reisfeld RA: Bispecific-monoclonal-antibody-directed lysis of ovarian carcinoma cells by activated human T lymphocytes. Cancer Immunol Immunother 33:210, 1991
12. Renner C, Jung W, Sahin U, Denfeld R, Pohl C, Trümper L, Hartmann F, Diehl V van Lier R, Pfreundschuh M: Cure of xenografted human tumors by bispecific monoclonal antibodies and human T-cells. Science 264:833, 1994
13. Jung W, Giner H, Fadle N, Arnold G, Pfreundschuh M: Reactivity of antibodies (mAbs) from the activation antigen clusters against native and recombinant human CD30 expressed on eukaryotic cells and selected peptide sequences of the CD30-antigen, in Schlossman (ed): Leucocyte Typing V. Oxford, UK, Oxford University Press, 1995
14. Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenolchloroform extraction. Anal Biochem 612:156, 1987
15. Sambrook J, Fritsch EF, Maniatis T: Molecular Cloning (2nd ed). Cold Spring Harbor NY, Cold Spring Harbor Laboratory Press, 1989
16. Winkler U, Gottstein C, Schön G, Kapp U, Hansmann M-L, Bohlen H, Thopre P, Diehl V, Engert A: Successful treatment of disseminated human Hodgkin's disease in SCID mice with deglycosylated ricin A-chain immunotoxins. Blood 83:466, 1994
17. Cause A, Pohl C, Tschiersch A, DaCosta, Jung W, Diehl V, Pfreundschuh M: Clinical significance of soluble CD30 antigen in the sera of patients with untreated Hodgkin's disease. Blood 77:1983, 1991
18. Martino G, Anastasi J, Feng J, McShan C, DeGroot L, Quintas J, Grimaldi LME: The fate of human peripheral blood lymphocytes after transplantation into SCID mice. Eur J Immunol 23:1023, 1993
19. Renner C, Pfreundschuh M: Treatment of Hodgkin tumors in SCID mice by a combination of human NK- or T-cells and bispecific antibodies. J Hematother 4:447, 1995
20. Renner C, Pfreundschuh M: Tumor therapy by immune recruitment with bispecific antibodies. Immunol Rev 145:179, 1995
21. Renner C, Jung W, van Lier R, Sahin U, Pfreundschuh M: The role of lymphocyte subsets and adhesion molecules in T-cell dependent cytotoxicity mediated by CD3 and CD28 bispecific monoclonal antibodies. Eur J Immunol 25:2027, 1995
22. Slivarck DJ, Ellis TM, Nawrocki N, Fisher RI: The impact of Hodgkin's disease on the immune system. Semin Oncol 17:673, 1990
23. Carde P, DaCosta L, Manil L, Pfreundschuh M, Lumbroso JD, Saccavini JC, Caillou B, Ricard M, Boudet, Hayat M, Diehl V, Parmentier P: Immunoscintigraphy of Hodgkin's disease: In vivo use of radiolabelled monoclonal antibodies derived from Hodgkin cell lines, Eur J Cancer 26:474, 1990
24. DeVita VT, Hubbard SM, Longo DL: The chemotherapy of lymphomas: Looking back, moving forward - the Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 47:5810, 1987